ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
Key Highlights: Closed business combination with Larkspur Health Acquisition Corp. in December 2022 and began trading on Nasdaq Global Market under the ticker symbol "ZVSA"Planning underway with nephrologists for an investigator-initiated clinical trial in focal segmental glomerulosclerosis ("FSGS") and up to two other renal populations to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200Recently published data in peer-reviewed journals detail the mechanism of action of inflammasome ASC inhibitor IC 100, and support its CNS activity in preclinical models of aging and Alzheimer's diseaseAdded three new Board members and three new members to Renal Scientific Advisory Board
